Serum response factor targets Cyr61 to facilitate chronic progression after ischemic acute kidney injury through renal tubular epithelial–myofibroblast transdifferentiation
Increased SRF/Cyr61 pathway activity promotes EMyT and dysfunction in renal tubular epithelial cells in the chronic progression after AKI. Targeting SRF with CCG-1423 may be an attractive therapeutic strategy in the chronic progression after AKI.
Authors
- Ying Xu (ORCID: https://orcid.org/0000-0001-6855-2934)
- Hong Luan
- Lin Che (ORCID: https://orcid.org/0009-0005-2619-9382)
- Xiaofei Man
- Long Zhao
- Hui Zhang (ORCID: https://orcid.org/0000-0001-8726-7098)
- Chenyu Li (ORCID: https://orcid.org/0000-0002-5402-584X)
- Bin Zhou (ORCID: https://orcid.org/0000-0001-5278-5522)
- Congjuan Luo (ORCID: https://orcid.org/0000-0003-1952-8668)
- Chengyu Yang (ORCID: https://orcid.org/0000-0002-1505-754X)
- Chen Guan (ORCID: https://orcid.org/0009-0003-0755-8461)
- Quandong Bu
- Lingyu Xu
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1186/s40001-025-03716-8
- Primary Topic
- Connective Tissue Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00